Developing Therapies
To Transform Lives

Audentes Therapeutics, an Astellas company, is developing genetic medicines for life-threatening diseases. We are committed to bringing transformative treatments to patients living with serious, rare neuromuscular conditions as rapidly as possible.

Watch the story of a family affected by a neuromuscular disease

Innovative Therapies

Our investigational therapies target rare diseases through three modalities: gene replacement, exon skipping gene therapy and vectorized RNA knockdown. We are leveraging Astellas’ global resources, industry leadership in immune biology, and deep scientific expertise to expand our reach and develop valuable new genetic medicines for patients around the world.

Courageous Patients

We depend on courageous patients and their families to advance our investigational therapies. Our patient communities are important partners and collaborators, informing our clinical trial programs and drug development process.

Zak Courageous Patient
Learn More

State-of-the-Art Facilities

The science of genetic medicines is complex. Our robust capabilities and industry leading manufacturing facilities put us at the forefront of developing innovative therapies.

Our People

We take pride in our mission to develop transformative genetic medicines to patients around the world. Our experienced team has the passion and drive to accomplish our goal of helping patients with life-threatening diseases. If you’re looking for a fast-paced work environment where employees whole heartedly embody a “Get Stuff Done” attitude, you’ll fit right in.

MEET OUR TEAM
JOIN OUR TEAM
MEET OUR TEAM
JOIN OUR TEAM

@AudentesTx

What bold things can you expect from us next? Keep track of company announcements, by following us on Twitter!

Learn more about what we’re doing to become the leader in the development and commercialization of innovative genetic medicines to treat serious rare neuromuscular diseases, the people who make it great and the exciting job opportunities available by following us on LinkedIn.